NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that the initial stage of a series of Phase I/II clinical trials of IMC-A12 in patients with advanced pancreatic cancer has opened for patient enrollment. The Southwest Oncology Group (SWOG), a cancer network sponsored by the National Cancer Institute (NCI), is evaluating IMC-A12, ImClone’s fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in a small Phase I study immediately followed by a much larger randomized Phase II trial.
